Solid Biosciences holds initial close of latest round
March 31, 2017
Biotechnology | Cambridge, MA | Series C
Life science company Solid Biosciences has completed the first close of a $50 million Series C financing, which it will use to develop its portfolio of therapies targeted at Duchenne muscular dystrophy. The company has also announced a merger with its previous subsidiary, Solid GT, which focuses on gene therapy development.